UE Grant Projects

Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.4  "Regional research agendas" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

Project is realized by Consortium comprising: Institute of Immunology and Experimental Therapy Polish Academy of Sciences in Wroclaw, Captor Therapeutics Inc

Value of the project: 4 314 375.00 PLN
European Union financing: 3 834 558.00 PLN

Goal and expected results of the project: development of scalable and sensitive high-throughput fluorescence assay allowing for rapid detection of active PROTAC compounds which induce degradation of pathological proteins.

Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.1  "Application projects" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

Project realized by Consortium comprising: The National Centre of Research and Development Ltd, Captor Therapeutics Inc

Value of the project: 4 968 788.76 PLN
European Union financing: 4 260 002.76 PLN

Goal and expected results:  development of two-stage high-throughput screening assay for low molecular weight compounds which induce targeted protein degradation.

Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and developmend work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund   

Value of project: 35 902 013.75 PLN
European Union financing: 27 683 098.00 PLN

Goal and expected results of the project: Development and testing in the first stage of clinical tests of low molecular weight chemical compounds which will be future drug candidates in tumor therapies of  non-small lung cancer and triple negative breast cancer.

Project: “Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies – stage II”  (FENG.01.01-IP.01-1002/23) 

The project is financed by European Funds for Smart Economy 2021-2027 (FENG), SMART Path. 

The project involves design and development of an innovative drug candidate that induces MCL-1 protein degradation via the proteasomal pathway. The project includes conducting preclinical studies and Phase Ia clinical trials. 

Purpose and planned outcomes of the project: To develop the dossier of the selected drug candidate for the treatment of cancers such as non-small lung cancer and triple negative breast cancer, along with toxicological and pharmacological data, and to conduct a Phase 1a clinical trial. 

Value of the project stage II : 7 802 294,00 PLN 
European Union financing: 4 976 940,75  PLN 

Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

Value of project: 37 130 943.75 PLN
European Union financing: 29 558 070.00 PLN

Goal and expected results of the project: Discovery and development novel, first in class oral drugs targeting key drivers of rheumatoid arthritis, psoriasis and ulcerative colitis.

Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

Value of project: 32 041 906.25 PLN
European Union financing: 25 510 680.00 PLN

Goal and expected results of the project: Development of first, oral targeted therapy focused on interruption of the main cause of colorectal cancer (CRC). The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.

Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

Value of the project: 36 389 016.25 PLN
European Union financing: 28 959 643.00 PLN

Goal of project: Development of a drug candidate in the treatment of hepatocellular carcinoma that allows the elimination of cancer cells through induced degradation of oncogenic transcription factor. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.

Project: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor - Stage II”. 

The project is financed by European Funds for Smart Economy 2021-2027 (FENG), SMART Path. 

The project involves the development of an oral drug/drug candidate for use in the treatment of patients with hepatocellular carcinoma (HCC). The project includes conducting preclinical studies and conducting Phase Ia clinical trials. 

Purpose and planned outcomes of the project : Development of a drug candidate for the treatment of hepatocellular carcinoma, allowing the elimination of cancer cells, through induced degradation of an oncogenic transcription factor. The drug candidate will be tested in Phase I clinical trials. 

Value of the project stage II : 12 351 378,40 PLN 
European Union financing: 6 766 157,95  PLN 

Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

Value of the project: 10 135 628.75 PLN
European Union financing: 7 759 469.50 PLN

Goal and expected results of the project: Development and implementation of technological platform through generation of modular small molecules capable of inducing protein degradation upon recruitment of novel ubiquitin ligases.

Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implementet by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

Value of the project: 34 441 900.00  PLN
European Union financing: 27 411 400.00 PLN

Goal and expected results of the project: Development of a drug candidate in the treatment of autoimmune diseases through generation of non-toxic ligase ligands. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.